Trial Profile
A Prospective, Multicenter, Randomized, Controlled, Open Trial, Parallel Groups (1: 1), With Subcutaneous Polimerized Mix (100/100), in Patients With Rhinoconjunctivitis Sensitized to the Following Combination of Pollen: Timothy Grass and Olea Europaea, and Administered by Different Schedules
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Allergy immunotherapy (Primary)
- Indications Rhinoconjunctivitis
- Focus Adverse reactions
- Sponsors Bial
- 02 Aug 2016 New trial record